Fidelity
Home > Boards > Free Zone > Health and Sciences > Biotech Values

InterMune ReadMeFirst

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ghmm Member Profile
Member Level 
Followed By 44
Posts 5,415
Boards Moderated 0
Alias Born 01/22/06
160x600 placeholder
Oil Futures Reach Six-Week High as Cushing Supplies Fall
Oil futures advanced to a six-week high Thursday as traders turned their focus from rising U.S. stockpiles to the continued drawdown of supplies from a storage hub in Oklahoma, where the benchmark U.S. contract is priced.
Top Equities Stories Of The Day
Client Balances at Morgan Stanley Wealth Management Near Merrill Lynch
Citi Picks Dewilde to Lead Asia Markets and Investor Services Business
Treasury Turns Its Gaze to Municipal-Bond Market
SanDisk, Weibo Gains Pace Tech Stocks
Sales of Johnson s New Hepatitis Drug Soars
U.S. Hot Stocks: Hot Stocks to Watch
Fast-Rising Costs Erode Google's Profits -- 3rd Update
European Stocks Turn Higher, But Rémy, Diageo Lag
ghmm Member Level  Saturday, 04/25/09 08:14:10 PM
Re: ghmm post# 74782
Post # of 176957 
InterMune ReadMeFirst

Edits: INFORM Info, EASL Abstracts

Call Summaries
#msg-19408521 Q1 2007
#msg-23131457 Q2 2007
#msg-24264853 Q3 2007
#msg-25836765 JP Morgan 26th Annual Healthcare Conference Notes
#msg-26491473 Wachovia 2008 Healthcare Conference
#msg-26701562 Q4 2007
#msg-29981789 Needham / Goldman Sachs 6/2008
#msg-31934416 Thomas Weisel Partners 9/4/08
#msg-33658397 LCM 11/08
#msg-34751687 191 Phase 1B triple combo results
#msg-34858414 JP Morgan 1/15/09
#msg-35347863 2/3/09 CAPACITY Trial Results Call/Presentation notes and Speculations
#msg-35922220 2/26/09 Q4 2008 Call/PR Notes
#msg-36393012 3/17/09 Cowen Health Care Conference Notes
#msg-37312942 4/25/09 EASL INFORM-1

OLD RMF
#msg-33516864
#msg-26702355

HCV
http://clinicaltrials.gov/ct2/show/NCT00801255 - INFORM Clinical Trials.gov
#msg-37309589 4/25/09 PR Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C
#msg-37306972 4/24/09 PR InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
#msg-37208214 4/21/09 PR INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
#msg-36388140 (EASL Abstract) FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1
#msg-36421384 (EASL Abstract) COMBINATION OF THE NS3/4A PROTEASE INHIBITOR ITMN-191 WITH THE ALLOSTERIC NS5B POLYMERASE INHIBITOR ITMN-8020 ENHANCES REPLICON CLEARANCE AND REDUCES THE EMERGENCE OF DRUG RESISTANT VARIANTS
#msg-36421330 (EASL Abstract) SUPPRESSION OF IN VITRO RESISTANCE DEVELOPMENT AFTER TREATMENT OF THE HCV REPLICON WITH NS3/4A INHIBITOR ITMN-191 (R7227) IN COMBINATION WITH NUCLEOSIDE INHIBITOR R7128 OR R1626
#msg-36421289 (EASL Abstract) INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN
#msg-36421248 (EASL Abstract) INTERFERON-GAMMA, INTERFERON-ALPHA AND RIBAVIRIN IN COMBINED THERAPY OF CHRONIC HEPATITIS C PATIENTS
#msg-34747018 InterMune Reports Results from Triple Combination Study of ITMN-191
#msg-33270432 (AASLD Poster) HCV NS3 helicase inhibitor screening
#msg-33270394 (AASLD Poster) phenotypic analysis of NS3 sequences
#msg-33270382 (AASLD Poster) ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors
#msg-33270355(AASLD Poster) PK-PD for ITMN-191 in a Phase 1 MAD
#msg-33270341 (AASLD Poster) ITMN-191 Phase 1b
#msg-33270294 (AASLD Poster) ITMN-191 Phase 1A
#msg-33270262 (AASLD Poster) ITMN-5489
#msg-33446127 INFORM-1 Trial Initiation
#msg-33497987 INFORM-1 Study information (from DB webcast), #msg-36349693 detail on cohorts.
#msg-33967428 INFORM-1 clinical trials.gov info
#msg-36388140 (EASL Abstract) INFORM-1, #msg-36393100 some commentary
#msg-36421384 (EASL Abstract) COMBINATION OF THE NS3/4A PROTEASE INHIBITOR ITMN-191 WITH THE ALLOSTERIC NS5B POLYMERASE INHIBITOR ITMN-8020 ENHANCES REPLICON CLEARANCE AND REDUCES THE EMERGENCE OF DRUG RESISTANT VARIANTS
#msg-36421330 (EASL Abstract) SUPPRESSION OF IN VITRO RESISTANCE DEVELOPMENT AFTER TREATMENT OF THE HCV REPLICON WITH NS3/4A INHIBITOR ITMN-191 (R7227) IN COMBINATION WITH NUCLEOSIDE INHIBITOR R7128 OR R1626
#msg-36421289 (EASL Abstract) INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN
#msg-36421248 (EASL Abstract) INTERFERON-GAMMA, INTERFERON-ALPHA AND RIBAVIRIN IN COMBINED THERAPY OF CHRONIC HEPATITIS C PATIENTS

IPF
#msg-35288566 CAPACITY Trial Results PR
#msg-34138706 Shionogi announced the launch of Pirespa (Pirfenidone)
#msg-33518800 Differences between Shionogi Phase 3 and CAPACITY (Pirfenidone Phase 3)
#msg-32898098 Shionogi received marketing approval

#msg-26702328 Competitive Landscape
#msg-32434359 Update on Actelion (Tracleer) enrollment/results timeline
#msg-30869320 Update on Actelion (Tracleer) some BUILD-3 details
#msg-33788471 JNJ
#msg-30792742 Gilead (Letairis)

Financials
154.7 Million (End of Q4) + 63.5 million 2/09 Financing
170 Debt (2 convertibles 85 million due March ’11 convert price $21.63 other 85 million due March ’15 convert price $18.88)
43.4 million shares outstanding (not counting converts – 8.432 million shares and options 4.6 million) As of 12/31/08

Upcoming Events
Q2 2009 (EASL): Present ITMN-191 Phase 1b triple combination study results
Q2 2009 (EASL): Present top-line results of available cohorts from INFORM-1
Q2 2009 (ATS): Present Pirfenidone results
Summer ’09: Roche to initiate Phase 2B study with ITMN-191 (R7227)
Summer ’09: Submit NDA to FDA for Pirfenidone
Q4 2009 (AASLD): Presentation of all cohorts of INFORM-1
End ’09: Submit NDA to MAA for Pirfenidone
Q4 ‘09/Q1 ’10: RVR data from 12 week cohort of Phase 2B R7227 study
Mid ’10: File IND for ITMN-520 (Pirfenidone Analog)


Company Website: http://www.intermune.com/wt/home
SEC Filings: http://tinyurl.com/8vdp2p
Most Recent 10-K: http://tinyurl.com/djxqq6


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist